COMMUNIQUÉS West-GlobeNewswire

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/08/2026
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs [...]
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20% Remaining performance [...]
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
12/08/2026
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with [...]
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
12/08/2026
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established [...]
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
12/08/2026
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and [...]
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to [...]
Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality
12/08/2026
COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, [...]
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
12/08/2026
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing [...]
Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
12/08/2026
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
12/08/2026
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference ( [...]
Anteris Technologies Announces Results for the Second Quarter of 2026
12/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
11/08/2026
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination ERAS-0015 [...]
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
11/08/2026
WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti- [...]
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
11/08/2026
Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite [...]

Pages